acute heart failure
Conditions
Brief summary
Days alive and outside hospital until day 30
Detailed description
1. Clinical benefit at 30 days, consisting of a composite of 1. all-cause death, 2. Readmission after discharge from initial hospitalization, 3. new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value), assessed using a Hierarchical win-ratio’ approach. 2. Days alive and outside hospital until day 90 3. Days of admittance in the primary admission
Interventions
DRUGMETOLAZONE
DRUGinert tablets identical with metolazone
DRUGAcetazolamide 500mg Powder for solution for Injection
DRUGSaline identical with acetazolamide
Sponsors
Region Hovedstaden, Region Hovedstaden
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Days alive and outside hospital until day 30 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinical benefit at 30 days, consisting of a composite of 1. all-cause death, 2. Readmission after discharge from initial hospitalization, 3. new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value), assessed using a Hierarchical win-ratio’ approach. 2. Days alive and outside hospital until day 90 3. Days of admittance in the primary admission | — |
Countries
Denmark
Outcome results
None listed